Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma
Corresponding Author
Misuzu Shimakage
Clinical Research Institute, National Hospital Organization, Osaka National Hospital, Chuo-ku, Osaka, Japan
Fax: +011-81-738-23-3104.
Department of Pediatrics, National Hospital Organization, Wakayama National Hospital, 1138 Wada, Mihama-Cho, Hidaka-gun, Wakayama 644-0044, JapanSearch for more papers by this authorNobumasa Inoue
Department of Internal Medicine, National Hospital Organization, Osaka National Hospital, Chuo-ku, Osaka, Japan
Search for more papers by this authorKohichi Ohshima
First Department of Pathology, Faculty of Medicine, Fukuoka University, Johnan-ku, Fukuoka, Japan
Search for more papers by this authorKunimitsu Kawahara
Department of Pathology, National Hospital Organization, Osaka National Hospital, Chuo-ku, Osaka, Japan
Search for more papers by this authorTakashi Oka
Department of Pathology, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
Search for more papers by this authorKazuta Yasui
Osaka Red Cross Blood Center, Joto-ku, Osaka, Japan
Search for more papers by this authorKayoko Matsumoto
Osaka Red Cross Blood Center, Joto-ku, Osaka, Japan
Search for more papers by this authorHirokazu Inoue
Department of Microbiology, School of Medicine, Shiga University of Medical Science, Tsukiwa-cho, Seta, Ohtsu, Japan
Search for more papers by this authorAkihiro Watari
Division of Cancer and Developmental Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
Search for more papers by this authorShinji Higashiyama
Division of Cancer and Developmental Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
Search for more papers by this authorMasuo Yutsudo
Division of Cancer and Developmental Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
Search for more papers by this authorCorresponding Author
Misuzu Shimakage
Clinical Research Institute, National Hospital Organization, Osaka National Hospital, Chuo-ku, Osaka, Japan
Fax: +011-81-738-23-3104.
Department of Pediatrics, National Hospital Organization, Wakayama National Hospital, 1138 Wada, Mihama-Cho, Hidaka-gun, Wakayama 644-0044, JapanSearch for more papers by this authorNobumasa Inoue
Department of Internal Medicine, National Hospital Organization, Osaka National Hospital, Chuo-ku, Osaka, Japan
Search for more papers by this authorKohichi Ohshima
First Department of Pathology, Faculty of Medicine, Fukuoka University, Johnan-ku, Fukuoka, Japan
Search for more papers by this authorKunimitsu Kawahara
Department of Pathology, National Hospital Organization, Osaka National Hospital, Chuo-ku, Osaka, Japan
Search for more papers by this authorTakashi Oka
Department of Pathology, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan
Search for more papers by this authorKazuta Yasui
Osaka Red Cross Blood Center, Joto-ku, Osaka, Japan
Search for more papers by this authorKayoko Matsumoto
Osaka Red Cross Blood Center, Joto-ku, Osaka, Japan
Search for more papers by this authorHirokazu Inoue
Department of Microbiology, School of Medicine, Shiga University of Medical Science, Tsukiwa-cho, Seta, Ohtsu, Japan
Search for more papers by this authorAkihiro Watari
Division of Cancer and Developmental Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
Search for more papers by this authorShinji Higashiyama
Division of Cancer and Developmental Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
Search for more papers by this authorMasuo Yutsudo
Division of Cancer and Developmental Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
Search for more papers by this authorAbstract
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma. Although this disease is initiated by infection with human T-lymphotropic virus type 1 (HTLV-1), many HTLV-1 carriers survive for a long period without aggressive illness, suggesting that other factors may play roles in the progression of ATLL to an aggressive state. However, the mechanism involved in this progression still remains unclear. Previously, we have reported that ASY/Nogo mRNA was markedly down-regulated in human small-cell lung carcinomas, whereas it was expressed in normal tissues and other lung carcinomas, such as adenocarcinoma and squamous cell carcinoma. To understand whether or not ASY/Nogo gene is involved in the progression of ATLL, we examined the expression of ASY/Nogo mRNA in smoldering, chronic and aggressive ATLL, and found that the expression level of ASY/Nogo mRNA was markedly reduced in clinically aggressive ATLL. HTLV-1 Tax expression was not affected by the down-regulation of ASY/Nogo mRNA. These results indicate that the ASY/Nogo gene may act as a suppressor against ATLL progression, independent of Tax expression. © 2006 Wiley-Liss, Inc.
References
- 1 Poietz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415–9.
- 2 Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481–92.
- 3 Shimoyama M, Members of Lymphoma Study Group. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia/lymphoma. Br J Haematol 1991; 79: 428–37.
- 4 Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, Jeang KT. Human T-cell leukemia virus type 1 tax and cell cycle progression: role of cyclin D-cdk and p110RB. Mol Cell Biol 1998; 18: 3620–32.
- 5 Pozzatti R, Vogel J, Jay G. The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells. Mol Cell Biol 1990; 10: 413–7.
- 6 Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Ann Rev Immunol 2001; 19: 475–96.
- 7 Jeang K-T, Giam C-Z, Majone F, Aboud M. Life, death and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004; 279: 31991–4.
- 8 Li Q, Qi B, Oka K, Shimakage M, Yoshioka N, Inoue H, Hakura A, Kodama K, Stanbridge EJ, Yutsudo M. Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer. Oncogene 2001; 20: 3929–36.
- 9 Chen MS, Huber AB, van der Haar ME, Frank M, Schnell AA, Christ F, Schwab ME. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibodyIN-1. Nature 2000; 403: 434–39.
- 10 GrandPre T, Nakamura F, Vartian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000; 403: 439–4.
- 11 Okamoto T, Ohno Y, Tsugane S, Watanabe S, Shimoyama M, Tajima K, Miwa M, Shimotohno K. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res 1989; 80: 191–5.
- 12 Nishimura S, Asou N, Suzushima H, Okubo T, Fujimoto T, Osato M, Yamasaki H, Lisha L, Takatsuki K. p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia. Leukemia 1995; 9: 598–604.
- 13 Fujiwara H, Arima N, Hashimoto-Tamaoki T, Matsushita K, Ohtsubo H, Arimura K, Hidaka S, Tei C. Alteration of p16 (CDKN2) gene is associated with interluekin-2-induced tumor cell growth in adult T-cell leukemia. Exp Hematol 1999; 27: 1004–9.
- 14 Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H, Matsuoka M. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res 2000; 15: 1043–8.
- 15 Nakayama K, Yamada Y, Koji T, Hayashi T, Tomonaga M, Kamihira S. Expression and phosphorylation status of retinoblastoma protein in adult T-cell leukemia/lymphoma. Leukemia Res 2000; 24: 299–305.
- 16 Arima N, Matsushita K, Obata H, Ohtsubo H, Fujiwara H, Arimura K, Kukita T, Suruga Y, Wakamatsu S, Hidakas, Tei C. NF-κB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Exp Hematol 1999; 27: 1168–75.
- 17 Tambe Y, Isono T, Haraguchi S, Yoshioka-Yamashita A, Yutsudo M, Inoue H. A novel apoptotic pathway induced by the drs tumor suppressor gene. Oncogene 2004; 23: 2977–87.
- 18 Tsujimoto Y, Ikegami N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 1987; 2: 3–7.
- 19 Inukai T, Inoue A, Kurosawa H, Goi K, Shinjyo T, Ozawa K, Mao M, Inaba T, Look A. SLUG, a ces-1-related zinc finger transcription gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 1999; 4: 343–52.
- 20 Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA. IL-2Rα-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Rα interaction. Cancer Res 2000; 15: 6977–84.
- 21 Tamiya S, Matsuoka M, Etoh K-I, Watanabe T, Kamihira S, Yamaguchi K, Takatsuki K. Two types of defective human T-lymphotropic virus type I (HTLV-I) provirus in adult T-cell leukemia. Blood 1996; 88: 3065–73.
- 22
Ohshima K,
Suzumiya J,
Izumo S,
Mukai Y,
Tashiro K,
Kikuchi M.
Detection of human T-lymphotropic virus type-I DNA and mRNA in lymph nodes; using polymerase chain reaction in situ hybridization (PCR/ISH) and reverse transcription (RT-PCR/ISH).
Int J Cancer
1996;
66:
18–23.
10.1002/(SICI)1097-0215(19960328)66:1<18::AID-IJC4>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
Citing Literature
